XOMA Royalty Corporation (XOMA)

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty CorporationApril 27, 2026 3:06 PM
PR Newswire (US)

NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold. The transaction is valued at approximately $739 million and is expected to close in the third quarter of 2026.If you are a stockholder of XOMA Royalty Corporation and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/xoma/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at info @weststar-1920 or 844-400-4643 (toll-free).Rowley Law PLLC represents stockholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.Attorney Advertising. Prior results do not guarantee a similar outcome.



View original content:https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-xoma-royalty-corporation-302754588.htmlSOURCE Rowley Law PLLC

Original: ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

XOMA shares climb after Q4 results top forecasts on strong royalty incomeMarch 18, 2026 10:14 AM
IH Market News
XOMA Royalty Corporation (NASDAQ:XOMA) posted fourth-quarter results that came in ahead of analyst expectations, supported by higher royalty receipts and milestone payments from its expanding portfolio of biotechnology assets.Shares of the company rose about 7% following the earnings announcement.The biotech royalty company reported earnings of $0.26 per share for the fourth quarter, well above the analyst consensus estimate of a loss of $0.11 per share. Revenue totaled $13.76 million, exceeding forecasts of $11.13 million and marking a 58% increase from the $8.7 million recorded in the same quarter a year earlier.For the full year 2025, XOMA generated more than $50 million in cash receipts, including $33.6 million from royalties and $16.9 million from milestone payments. Total cash receipts increased 9% compared with 2024, while royalty income rose 68%.“We continue to search for innovative ways to drive enhanced optionality in the XOMA portfolio, with the addition of 22 assets and two platform technologies over the past year,” stated Owen Hughes, Chief Executive Officer. “With multiple commercial assets delivering growing royalty receipts, we achieved positive cash flow from operations and were able to return $16 million of capital through a share buyback in 2025.”Total revenue for the year reached $52.1 million, compared with $28.5 million in 2024, largely driven by higher income tied to VABYSMO and OJEMDA, as well as milestone payments from Rezolute and Takeda. General and administrative expenses rose to $36.1 million from $34.5 million, partly reflecting increased business development activity and ongoing litigation with Janssen Biotech.During 2025, the company completed seven acquisitions, securing $11.7 million in non-dilutive capital and obtaining economic interests tied to as much as $1.1 billion in potential milestone payments. XOMA ended the quarter with $133.7 million in cash and cash equivalents.XOMA Royalty Corporation stock price

Original: XOMA shares climb after Q4 results top forecasts on strong royalty income

XOMA $29.85 — bouncing from the Dec 11 RZLT drop ($25.39), filling the gap but $31 is key for trend confirmation. Don’t forget the preferreds (XOMAO/XOMAP) just paid $0.52+ per quarter (~8% yield), so income investors are covered. Common stock is showing life thanks to growing royalties from Vabysmo & Ojemda (~$38M) and new acquisitions like Mural Oncology & Turnstone, which add optionality while partners take the R&D risk. The Pomerantz probe is a caution flag, but long-term, XOMA is a portfolio play, not a single-trial biotech. Dip $28 = buy, stop $27, target $35–$36 if approvals & milestones hit. Patience still pays here. 🚀

XOMA approaching new 52=0 week high

XOMA new 52 week high

DOUBLE POST PLEASE DELETE ..

https://news.yahoo.com/gma/virginia-experiencing-statewide-outbreak-serious-163550888.html . . . . XOMA, USED TO BE IN TRIALS FOR THIS INDICATION ..

Keeps going up ?????

Up

https://abcnews.go.com/Health/antibody-therapies-cut-deaths-reduce-exposure-covid-19/story?id=75489999&cid=social_fb_abcn&fbclid=IwAR3XmMyE72XnwruiQkdXo5bW7v1o8Vu70oVSvyOgI1D4VXLHbpj1X4X0rUs

Novartis bought over half a million shares of XOMA! Wow!

Hmm sell or rocket to 43??

Xoma

Broke the average along with a solid report

Xoma

Nice up
News ?
Xoma

Whats with the gap?
Xoma

Could climb to 60 if the cancer trials go well years to come
Xoma

Wow 19 hit
Xoma

Up today xoma

News: $XOMA XOMA to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

EMERYVILLE, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 H.C. Wainwright Global Life Sciences in London, United Kingdom.  The pres...

In case you are interested https://marketwirenews.com/news-releases/xoma-to-present-at-the-2019-h-c-wainwright-global-life-sciences-conference-7938960.html

Nice xoma

Nice. Up time again ?
Xoma

Figured that $13 "deal" wouldn't last long

Hmmm xoma

Received message as a transaction in my account yesterday

"STOCK SPIN-OFF RECEIVED: XOMA CORP DEL RIGHT EXP 12/31/2088"

Anybody know what this means? Is this the right to buy at $13 per:

http://investors.xoma.com/news-releases/news-release-details/xoma-announces-commencement-rights-offering

The word "spin-off" has me confused

Wtf xoma

Wtf bumner
Xoma

Wow xoma

Boom nice up xoma

Good news
Xoma

Trading it. Must be. 16-18 range. Down.

Xoma

What gives

Ok this is killing me now.

Dang
Xoma

Wozaaa

Huge news
Awsome
Xoma

Huge news
Hope this helps

Xoma

Huge news!!
Russel

????huge news
Xoma

HUGE NEWS
CONGRATS!!!
Xoma

I keep looking at it and try and get excited but can’t seem to get there. if there is a move it will be quick and downside risk remains to strongly for me. best of luck i will be a spectator in this one.

daily looks nice but we should know by next week what the stock will do. still out for now.

News ?

Xoma

what a pumper

What is this news ?

Volume shows a steady rise up
Xoma

geeze now I really want to buy this stock

looks like a lot of dilution coming

Its at the red line

Xoma

there could still be money to be made here. full disclosure i almost bought a share today.

Market is correcting. Will be a rockey year. Look at a five year chart of the dow.

Xoma.
Long

bought at 22.78. this was uncalled for drop. Still volatile. One more license agreement and back uo to 30